INFLUENCE OF THE ENRICHED KEFIR PRODUCTS ON ENTEROBAKTERIA DEVELOPMENT

Nowadays dysbiotic complications are spread all over the world. They are usually accompanied by acute intestinal infections. The main infectious agents of acute intestinal infections of bacterial origin are microorganisms of the family Enterobacteriaceae . Functional fermented milk products are used to prevent such disorders. They help restore good intestinal microflora. The authors developed a production technology of fermented milk bioproducts that contain probiotics (bifidobacteria B.bifidum, B.longum, B.breve ), lactulose as prebiotic and immunoglobulin «Lactoglobulin against Potentially Pathogenic Bacteria and Salmonella». These products can not only restore «friendly» bacteria (lakto-and bifidobacteria) in intestine, but also suppress the development of potentially pathogenic microflora. The given article reveals how enriched kefir drinks influence bacteria of Enterobacteriaceae family. The authors used the method of comparing the developing mixed populations with the growth of the test strain in a monoculture based on liquid nutrient mediums with further inoculation on the solid nutrient mediums. The authors established the ability of the enriched kefir bioproducts to inhibit the development and multiplication of bacteria of the family Enterobacteriaceae , namely Salmonella typhimurium , Proteus mirabilis No. 878 (035), Escherichia coli 3912/41, Shigella sonnei (S-form) at simultaneous incubation on the solid mediums within 24 hours at 370. The analysis of the research results demonstrates that kefir products enriched with lactulose (which stimulates growth and development of bifido- and lactobacteria, that are present in the kefir drink and have antagonistic effect on enterobacteria) and immunoglobulin «Lactoglobulin» (which has antibodies to the potentially pathogenic bacteria and salmonella) are most capable of suppressing the development of pathogenic and potentially pathogenic enterobacteria, inhibiting their growth and multiplication, in comparison with the reference sample. The obtained results allow to assume that the developed products can be used to prevent and correct the negative changes in intestinal microflora and dysbiotic complications including acute intestinal infections caused by the representatives of the family Enterobacteriaceae.